626 results on '"Kasimir-Bauer, Sabine"'
Search Results
2. Molecular Characterization of Single Circulating Tumor Cells in Breast and Ovarian Cancer
3. Ratios of monocytes and neutrophils to lymphocytes in the blood predict benefit of CDK4/6 inhibitor treatment in metastatic breast cancer
4. Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse
5. Molecular Characterization of Single Circulating Tumor Cells in Breast and Ovarian Cancer
6. Multimodality in liquid biopsy: does a combination uncover insights undetectable in individual blood analytes?
7. Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
8. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis
9. Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer
10. A proposal for score assignment to characterize biological processes from mass spectral analysis of serum
11. High serum levels of periostin are associated with a poor survival in breast cancer
12. Integrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer
13. Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes
14. ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer
15. Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients
16. The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management
17. Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy
18. Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma
19. The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer
20. The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients
21. HLA-G 3′ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer
22. Elevated sHLA-G plasma levels post chemotherapy combined with ILT-2 rs10416697C allele status of the sHLA-G-related receptor predict poorest disease outcome in early triple-negative breast cancer patients
23. Abstract 2140: DNA damage response in circulating tumor cells shows predictive value for metastatic breast cancer patients receiving CDK4/6 inhibitors
24. Abstract 6693: Stability of urinary cell-free DNA and detection of T790M variant
25. Increase in Circulating MicroRNA Levels in Blood of Ovarian Cancer Patients
26. Supplementary Data from Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer
27. Supplementary Table 1 from Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer
28. Correlation between Imaging Markers Derived from PET/MRI and Invasive Acquired Biomarkers in Newly Diagnosed Breast Cancer
29. Abstract PD11-03: PD11-03 Comparison of a mono Atezolizumab window followed by Atezolizumab and chemotherapy with Atezolizumab and chemotherapy in triple negative breast cancer – an interim analysis of the adaptive randomized neoadjuvant trial NeoMono
30. Abstract P5-02-50: Do thymidine kinase 1 (TK1) plasma concentration and activity play a role in therapy management of metastatic breast cancer patients treated with CDK4/6 inhibitors?
31. Abstract P5-02-25: Transcriptional profiling of CTCs in metastatic breast cancer patients in the course of CDK4/6 inhibition
32. Intraindividual right–left comparison of sonographic features in polycystic ovary syndrome (PCOS) diagnosis
33. Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance
34. The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
35. Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer
36. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer
37. Circulating tumor cells in breast cancer
38. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA
39. Single nucleotide polymorphisms of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential translational aspects
40. Maternal serum copeptin, MR-proANP and procalcitonin levels at 11–13 weeks gestation in the prediction of preeclampsia
41. Detection of ESR1 Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients
42. In Early Breast Cancer, the Ratios of Neutrophils, Platelets and Monocytes to Lymphocytes Significantly Correlate with the Presence of Subsets of Circulating Tumor Cells but Not with Disseminated Tumor Cells
43. Looking at p53: Theoretical Implications and Methodological Aspects
44. The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer
45. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer
46. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients
47. Abstract 6256: Longitudinal transcriptional profiling of CTCs in metastatic breast cancer patients receiving CDK4/6 inhibitors to predict response
48. Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse
49. Detection of disseminated tumor cells in bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer
50. Combinatorial Power of cfDNA, CTCs and EVs in Oncology
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.